Skip to main content

Table 3 MTD finding of ALT-803 in combination with M7824

From: Quick efficacy seeking trial (QuEST1): a novel combination immunotherapy study designed for rapid clinical signal assessment metastatic castration-resistant prostate cancer

Dose-Escalation Schedule
Dose Level ALT-803 M7824
Level − 1 8 mcg/kg s.c. 1200 mg i.v.
Level 1 10 mcg/kg s.c. 1200 mg i.v.
Level 2 15 mcg/kg s.c. 1200 mg i.v.